AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23563246 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed recall test (New York University Paragraph Recall Test)
Number of subjects: 426
Study 23563246 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial temporal lobe atrophy (MTA) on MRI
Number of subjects: 426
Study 23563246 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 426
Study 23563246 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE ε4 allele presence
Number of subjects: 426
Study 23563246 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular risk factors, WMH, and lacunes on MRI
Number of subjects: 426
Study 20598442 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride 60-120mg/day
Number of subjects: 350
Study 20598442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 19357804 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone for patients without elevated cTnT
Number of subjects: 192
Study 19357804 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis for patients with elevated cTnT
Number of subjects: 192
Study 16464390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 29
Study 16464390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 29
Study 16464390 — intervention group
Group type: COMPARATOR
Intervention: Control (5% glucose)
Number of subjects: 29
Study 16464390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine vs Dobutamine
Number of subjects: 29
Study 15181850 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 + 5-Fu
Number of subjects: 0
Study 15181850 — intervention group
Group type: COMPARATOR
Intervention: 5-Fu
Number of subjects: 0
Study 15181850 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2
Number of subjects: 0
Study 11866422 — intervention group
Group type: EXPERIMENTAL
Intervention: Small volume resuscitation fluids (SVR) - a combination of hypertonic crystalloid with a colloid; specific dosage and duration not mentioned.
Number of subjects: 0
Study 11866422 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (HSD); specific dosage and duration not mentioned.
Number of subjects: 0
Study 11866422 — intervention group
Group type: COMPARATOR
Intervention: Meta-analysis and sub-group analysis; specific intervention not applicable.
Number of subjects: 0
Study 9236961 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized assessment and counseling with a written personal health plan
Number of subjects: 237
Study 9236961 — intervention group
Group type: COMPARATOR
Intervention: Standardized assessment without additional counseling or health plan
Number of subjects: 237
Study 7678715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary mitoxantrone
Number of subjects: 29
Study 7678715 — intervention group
Group type: COMPARATOR
Intervention: Intracavitary bleomycin
Number of subjects: 29
Study 3314372 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cerebellar stimulation (CCS)
Number of subjects: 20
Study 3314372 — intervention group
Group type: COMPARATOR
Intervention: Control (switch 'off')
Number of subjects: 20
Study 30297322 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose metronidazole (2 g)
Number of subjects: 623
Study 30297322 — intervention group
Group type: COMPARATOR
Intervention: 7-day-dose metronidazole (500 mg twice daily for 7 days)
Number of subjects: 623
Study 26369660 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic wire navigation (MWN)
Number of subjects: 40
Study 26369660 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 40
Study 24750798 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite coated screws
Number of subjects: 54
Study 24750798 — intervention group
Group type: COMPARATOR
Intervention: Standard screws
Number of subjects: 54
Study 22830646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunchtime walking intervention in an urban environment, twice a week for 8 weeks
Number of subjects: 0
Study 22830646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunchtime walking intervention in a natural environment, twice a week for 8 weeks
Number of subjects: 0
Study 22830646 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study 22830646 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected walking routes during lunch breaks in phase 2
Number of subjects: 0
Study 22830646 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer monitoring of physical activity
Number of subjects: 0
Study 20932208 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 108
Study 20932208 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT+MS
Number of subjects: 108
Study 18533183 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg mCPP with ritanserin pre-treatment
Number of subjects: 20
Study 18533183 — intervention group
Group type: COMPARATOR
Intervention: mCPP administration
Number of subjects: 20
Study 15674303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 g WA
Number of subjects: 36
Study 15674303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g WA
Number of subjects: 36
Study 15674303 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g WA
Number of subjects: 36
Study 15674303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g WA (long-term administration)
Number of subjects: 36
Study 15674303 — intervention group
Group type: COMPARATOR
Intervention: 0 g WA (control for long-term administration)
Number of subjects: 36
Study 12083587 — intervention group
Group type: EXPERIMENTAL
Intervention: IV parecoxib sodium 40 mg
Number of subjects: 208
Study 12083587 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 4 mg
Number of subjects: 208
Study 12083587 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 30 mg
Number of subjects: 208
Study 12083587 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 208
Study 10099995 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% O2
Number of subjects: 1380
Study 10099995 — intervention group
Group type: COMPARATOR
Intervention: 20% O2
Number of subjects: 1380
Study 8924965 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-1A
Number of subjects: 131
Study 2150677 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil obturation technique
Number of subjects: 80
Study 2150677 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation
Number of subjects: 80
Study 348229 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephaloridine (3 doses of 1 g each: 1 g IV at surgery start, 1 g IM at 6 hours, 1 g IM at 12 hours)
Number of subjects: 100
Study 348229 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephaloridine (3 doses of 1 g each)
Number of subjects: 100
Study 31150497 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg
Number of subjects: 17
Study 31150497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 26768233 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (dietary counselling twice by telephone and access to twice‐weekly exercise groups)
Number of subjects: 606
Study 26768233 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal care (control group)
Number of subjects: 606
Study 26768233 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 606
Study 26768233 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention and control
Number of subjects: 606
Study 27411014 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (glucocorticoid)
Number of subjects: 0
Study 27411014 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (in vitro)
Number of subjects: 0
Study 25741842 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml HES 130/0.4
Number of subjects: 105
Study 25741842 — intervention group
Group type: COMPARATOR
Intervention: 1500 ml 9‰ saline solution
Number of subjects: 105
Study 22577064 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MWT (Six-Minute Walk Test) performed at home
Number of subjects: 173
Study 22577064 — intervention group
Group type: COMPARATOR
Intervention: Single 6MWT performed at weeks 8 and 26
Number of subjects: 173
Study 22577064 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 PF score
Number of subjects: 173
Study 20955443 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib
Number of subjects: 34701
Study 20955443 — intervention group
Group type: COMPARATOR
Intervention: diclofenac
Number of subjects: 34701
Study 20955443 — intervention group
Group type: EXPERIMENTAL
Intervention: not available
Number of subjects: 34701
Study 19022992 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-vasectomy group
Number of subjects: 58
Study 19022992 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 16091706 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐milk (daily approx. 0.2 l with the level 2.5 ppm)
Number of subjects: 510
Study 16091706 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 510
Study 16091706 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐milk
Number of subjects: 510
Study 12585183 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and Chinese herbal medicine (CHM)
Number of subjects: 114
Study 12585183 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate and Chinese herbal medicine (CHM)
Number of subjects: 114
Study 10941859 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BT) 1.2 ml injected endoscopically
Number of subjects: 5
Study 10941859 — intervention group
Group type: COMPARATOR
Intervention: Saline 1.2 ml injected endoscopically (Control)
Number of subjects: 5
Study 8749123 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ethanol (0.45 g/kg LBW)
Number of subjects: 4
Study 8749123 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose ethanol (0.80 g/kg LBW)
Number of subjects: 4
Study 8749123 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ethanol (1.05 g/kg LBW)
Number of subjects: 4
Study 8749123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 1331632 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-led primary home care and home assistance service on a 24-hour basis
Number of subjects: 249
Study 1331632 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 249
Study 4061105 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg four times daily
Number of subjects: 12
Study 4061105 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 60 mg four times daily
Number of subjects: 12
Study 4061105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diltiazem and propranolol (90 mg and 60 mg respectively, both four times daily)
Number of subjects: 12
Study 4061105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31355878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP control (target BP < 120/80 mm Hg)
Number of subjects: 1263
Study 31355878 — intervention group
Group type: COMPARATOR
Intervention: Standard BP control (target BP < 140/90 mm Hg)
Number of subjects: 1263
Study 31355878 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of intensive BP control
Number of subjects: 1263
Study 30505414 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical-site injections (SIs) with a mixture of epinephrine hydrochloride, morphine sulfate, ropivacaine HCL, and normal saline.
Number of subjects: 50
Study 30505414 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical-site injections (SIs)
Number of subjects: 50
Study 30505414 — intervention group
Group type: COMPARATOR
Intervention: No surgical-site injections (no-SI)
Number of subjects: 50
Study 30505414 — intervention group
Group type: COMPARATOR
Intervention: Surgical-site injections (SIs) and no-SI
Number of subjects: 50
Study 26693818 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 106
Study 26693818 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy with spironolactone addition
Number of subjects: 106
Study 26693818 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete RDN
Number of subjects: 106
Study 26693818 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone addition
Number of subjects: 106
Study 24359050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexketoprofen trometamol with paracervical block
Number of subjects: 120
Study 24359050 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular dexketoprofen trometamol without paracervical block
Number of subjects: 120
Study 24359050 — intervention group
Group type: COMPARATOR
Intervention: Intracavitary lidocaine instillation with paracervical block
Number of subjects: 120
Study 24359050 — intervention group
Group type: COMPARATOR
Intervention: Intracavitary lidocaine instillation without paracervical block
Number of subjects: 120
Study 23715650 — intervention group
Group type: EXPERIMENTAL
Intervention: Pringle manoeuvre
Number of subjects: 252
Study 23715650 — intervention group
Group type: COMPARATOR
Intervention: Hemi-hepatic vascular inflow occlusion
Number of subjects: 252
Study 21242684 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy with overhydration value (OH) revealed to patients and nurses
Number of subjects: 160
Study 21242684 — intervention group
Group type: COMPARATOR
Intervention: Standard methods without revealing OH values
Number of subjects: 160
Study 19723992 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral tunnel in the eleven o'clock position
Number of subjects: 30
Study 19723992 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral tunnel in the ten o'clock position
Number of subjects: 30
Study 19723992 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 17604559 — intervention group
Group type: EXPERIMENTAL
Intervention: Active biofeedback
Number of subjects: 38
Study 15208157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.45 g/kg b.w.) with placebo
Number of subjects: 7
Study 15208157 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.45 g/kg b.w.) with propranolol (40 mg at 08:00 and 20 mg at 12:00)
Number of subjects: 7
Study 15208157 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 7
Study 15208157 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ingestion
Number of subjects: 7
Study 11998300 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio alarm
Number of subjects: 47
Study 11998300 — intervention group
Group type: COMPARATOR
Intervention: Vibration alarm
Number of subjects: 47
Study 9602954 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg daily for 3 days)
Number of subjects: 12
Study 9602954 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (100 mg)
Number of subjects: 12
Study 8640469 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVP-I) used on mothers during perinatal period
Number of subjects: 8
Study 2264190 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7016928 — intervention group
Group type: EXPERIMENTAL
Intervention: guanabenz plus hydrochlorothiazide
Number of subjects: 52
Study 7016928 — intervention group
Group type: COMPARATOR
Intervention: guanabenz plus placebo
Number of subjects: 52
Study 31506757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysregulated sleep
Number of subjects: 319
Study 31506757 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of dysregulated sleep
Number of subjects: 319
Study 31506757 — intervention group
Group type: EXPERIMENTAL
Intervention: More severe internalizing problems
Number of subjects: 319
Study 31506757 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-specific elevations in dysregulated sleep
Number of subjects: 319
Study 31506757 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-specific elevations in anxiety and depression severity
Number of subjects: 319
Study 31677537 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Norepinephrine (NEP) with IV fluids
Number of subjects: 101
Study 31677537 — intervention group
Group type: COMPARATOR
Intervention: Late Norepinephrine (NEP) after failed fluids trial
Number of subjects: 101
Study 28732546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-restriction educational intervention group (60 participants)
Number of subjects: 120
Study 28732546 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (60 participants)
Number of subjects: 120
Study 26374231 — intervention group
Group type: EXPERIMENTAL
Intervention: COSMOS intervention (2-day education program including written guidelines, repeated theoretical and practical training, case discussions, and role play)
Number of subjects: 571
Study 26374231 — intervention group
Group type: COMPARATOR
Intervention: Current best practice (control group)
Number of subjects: 571
Study 23586852 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot intervention
Number of subjects: 6
Study 23586852 — intervention group
Group type: COMPARATOR
Intervention: Human trainer intervention
Number of subjects: 6
Study 21162685 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-iodine diet for 2 weeks
Number of subjects: 46
Study 21162685 — intervention group
Group type: COMPARATOR
Intervention: Low-iodine diet for 3 weeks
Number of subjects: 46
Study 21162685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (2 weeks and 3 weeks)
Number of subjects: 46
Study 19395396 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session standardised curriculum ('Unplugged')
Number of subjects: 6359
Study 19395396 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6359
Study 17198072 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopic liver biopsy
Number of subjects: 857
Study 17198072 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous liver biopsy
Number of subjects: 857
Study 15025403 — intervention group
Group type: EXPERIMENTAL
Intervention: TNX-901 (450 mg)
Number of subjects: 84
Study 15025403 — intervention group
Group type: EXPERIMENTAL
Intervention: TNX-901 (150 mg)
Number of subjects: 84
Study 15025403 — intervention group
Group type: EXPERIMENTAL
Intervention: TNX-901 (300 mg)
Number of subjects: 84
Study 15025403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 11242179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (80 mg of trimethoprim and 400 mg of sulphamethoxazole daily)
Number of subjects: 100
Study 11242179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9745421 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg
Number of subjects: 402
Study 9745421 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 600 mg
Number of subjects: 402
Study 9745421 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 600 mg (diet-only subset)
Number of subjects: 402
Study 9745421 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 200 mg (sulfonylurea subset)
Number of subjects: 402
Study 9745421 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg (sulfonylurea subset)
Number of subjects: 402
Study 9745421 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 600 mg (sulfonylurea subset)
Number of subjects: 402
Study 9745421 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg and 600 mg
Number of subjects: 402
Study 9745421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 7828971 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.9 mm inner, 2.9 mm (9F) outer diameter Fresenius tube
Number of subjects: 76
Study 7828971 — intervention group
Group type: COMPARATOR
Intervention: 3.0 mm inner, 4.0 mm (12F) outer diameter Bower polyurethane tube
Number of subjects: 76
Study 7828971 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG feeding
Number of subjects: 76
Study 7828971 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG procedure
Number of subjects: 76
Study 7828971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing time for PEG care
Number of subjects: 76
Study 2109465 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.5 mg i.v.)
Number of subjects: 128
Study 2109465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 2109465 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 128
Study 6994518 — intervention group
Group type: EXPERIMENTAL
Intervention: Levallorphan
Number of subjects: 0
Study 6994518 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 6994518 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiphenazole
Number of subjects: 0
Study 6994518 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 0
Study 31669449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid clinical trial design integrating traditional randomized controlled trial with pragmatic design aspects
Number of subjects: 0
Study 31669449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid designs in vaccine development
Number of subjects: 0
Study 31513232 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use in North America
Number of subjects: 9670
Study 28385433 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified edentulous treatment (SET)
Number of subjects: 64
Study 28385433 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 64
Study 25609193 — intervention group
Group type: EXPERIMENTAL
Intervention: Trelagliptin (100 mg once per week)
Number of subjects: 357
Study 25609193 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (25 mg once per day)
Number of subjects: 357
Study 25609193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 23896675 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated clinical prediction rule tool
Number of subjects: 0
Study 21366599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal phototherapy (three times a week for 2 weeks)
Number of subjects: 31
Study 21366599 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine HCl (180 mg per day for 2 weeks)
Number of subjects: 31
Study 19711095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nebulized bronchodilators (BD)
Number of subjects: 12